Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer group 2D ligands (NKG2DLs) are a family of cell surface proteins recognized by the activating receptor NKG2D, expressed on NK cells and certain T cell subsets. They mark stressed, infected, or transformed cells for destruction by cytotoxic lymphocytes. The main families include MICA/MICB and ULBP1-ULBP6 (RAET1 family). They are upregulated in response to cellular stress, infection, DNA damage, or transformation. Binding to NKG2D triggers cytotoxicity and cytokine secretion. In cancer, tumors may evade immunity by shedding soluble ligands or downregulating surface expression. Polymorphisms in MICA are associated with transplant outcomes.
NKG2DLs are ligands that bind to the NKG2D receptor on NK cells and T cells, triggering cytotoxicity and cytokine secretion, leading to targeted killing of the ligand-expressing cell. Some therapies may target the NKG2D/NKG2DL axis to enhance or suppress immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural Killer Group 2D Ligands (NKG2DL).